Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBIT: 2009-2025

Historic EBIT for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$23.3 million.

  • Myriad Genetics' EBIT fell 16.50% to -$23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$420.5 million, marking a year-over-year decrease of 263.13%. This contributed to the annual value of -$123.5 million for FY2024, which is 52.02% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' EBIT is -$23.3 million, which was up 92.92% from -$329.2 million recorded in Q2 2025.
  • Myriad Genetics' 5-year EBIT high stood at -$17.8 million for Q2 2022, and its period low was -$329.2 million during Q2 2025.
  • Moreover, its 3-year median value for EBIT was -$36.5 million (2024), whereas its average is -$69.3 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 69.55% in 2021, then slumped by 801.92% in 2025.
  • Myriad Genetics' EBIT (Quarterly) stood at -$43.1 million in 2021, then fell by 21.11% to -$52.2 million in 2022, then surged by 39.85% to -$31.4 million in 2023, then decreased by 24.20% to -$39.0 million in 2024, then fell by 16.50% to -$23.3 million in 2025.
  • Its EBIT stands at -$23.3 million for Q3 2025, versus -$329.2 million for Q2 2025 and -$29.0 million for Q1 2025.